Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma

Autor: Yingwei Hu, Jianbo Pan, Punit Shah, Minghui Ao, Stefani N. Thomas, Yang Liu, Lijun Chen, Michael Schnaubelt, David J. Clark, Henry Rodriguez, Emily S. Boja, Tara Hiltke, Christopher R. Kinsinger, Karin D. Rodland, Qing Kay Li, Jiang Qian, Zhen Zhang, Daniel W. Chan, Hui Zhang, Akhilesh Pandey, Amanda Paulovich, Andrew Hoofnagle, Bing Zhang, D.R. Mani, Daniel C. Liebler, David F. Ransohoff, David Fenyo, David L. Tabb, Douglas A. Levine, Eric Kuhn, Forest M. White, Gordon A. Whiteley, Heng Zhu, Ie-Ming Shih, Jasmin Bavarva, Jason E. McDermott, Jeffrey Whiteaker, Karen A. Ketchum, Karl R. Clauser, Kelly Ruggles, Kimberly Elburn, Li Ding, Linda Hannick, Lisa J. Zimmerman, Mark Watson, Mathangi Thiagarajan, Matthew J.C. Ellis, Mauricio Oberti, Mehdi Mesri, Melinda E. Sanders, Melissa Borucki, Michael A. Gillette, Michael Snyder, Nathan J. Edwards, Negin Vatanian, Paul A. Rudnick, Peter B. McGarvey, Philip Mertins, R. Reid Townsend, Ratna R. Thangudu, Richard D. Smith, Robert C. Rivers, Robert J.C. Slebos, Samuel H. Payne, Sherri R. Davies, Shuang Cai, Stephen E. Stein, Steven A. Carr, Steven J. Skates, Subha Madhavan, Tao Liu, Xian Chen, Yingming Zhao, Yue Wang, Zhiao Shi

Publikováno v: Cell Reports, Vol 33, Iss 3, Pp 108276- (2020)

Summary: Many gene products exhibit great structural heterogeneity because of an array of modifications. These modifications are not directly encoded in the genomic template but often affect the functionality of proteins. Protein glycosylation plays

Externí odkaz: https://doaj.org/article/687878b78b8f4a70bfe6276db55dbef8

Data from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Autor: Matthew J.C. Ellis, Hussam Al-Kateb, Philippe L. Bedard, Kimberly Blackwell, Mark Pegram, Daniel F. Hayes, John Pfeifer, Alshad S. Lalani, Richard Bryce, Richard B. Lanman, Kimberly C. Banks, Caroline Bumb, Jill Anderson, Shana Thomas, Polly Ann Niravath, Carey Anders, Timothy J. Pluard, Andres Forero, Melody Cobleigh, Debu Tripathy, Christy Russell, Matthew P. Goetz, Michael Naughton, Eric Winer, Gretchen Kimmick, Melinda L. Telli, Rachel A. Freedman, Feng Gao, Ron Bose, Cynthia X. Ma

Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::051f6f4caa8d2642629b11b5a860729c
https://doi.org/10.1158/1078-0432.c.6526515.v1

NF-ϰB-independent activation of β-interferon expression in mouse F9 embryonal carcinoma cells

Autor: Matthew J.C. Ellis, Stephen Goodbourn

Publikováno v: Nucleic Acids Research. 22:4489-4496

We have examined the behaviour of the beta-interferon promoter in mouse F9 embryonal carcinoma cells. In undifferentiated cells, the beta-interferon promoter is not responsive to dsRNA or to Sendai virus. In cells stimulated to differentiate into par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e1a8c639f20b4b9615b7c9d032a704
https://doi.org/10.1093/nar/22.21.4489